Market Research Logo

Tardive Dyskinesia Market Report: Focus on US & Japan (2016-2025)

Tardive Dyskinesia Market Report: Focus on US & Japan (2016-2025)

Tardive dyskinesia is an involuntary movement disorder that typically arises from the long-term use of antipsychotic medication in schizoaffective disorders. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, trunk, or extremities, including lip smacking, grimacing, tongue protrusion, facial movements or blinking, puckering and pursing of the lips. TDs are most common in patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have been treated with antipsychotic medication for long periods, but they occasionally occur in other patients as well.

The key factors driving the growth of the Tardive dyskinesia market are rising schizophrenia patients, increasing bipolar patients, growing antipsychotic prescription, increased use of long-term neuroleptic drugs and increasing incidence of neurological disorders. However, the expansion of the market is hindered by side effects of drugs and under-diagnosed.

The report “Tardive Dyskinesia Market” provides a comprehensive study of the US and Japan tardive dyskinesia market with detailed analysis of market size, growth and penetration of the industry. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The industry comprises few large players such as Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceuticals Industries Ltd. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth."


1. Tardive Dyskinesias - An Overview
1.1 Antipsychotics Overview
Table 1: Side Effects of Antipsychotics
1.2 Tardive Dyskinesias
1.3 Signs and Symptoms
Table 2: Signs and Symptoms of Tardive Dyskinesias
1.4 Causes
1.5 Treatment
1.6 Existing and Pipeline Drugs
2. The US Tardive Dyskinesia Market Analysis
2.1 The US Tardive Dyskinesia Market by Number of Patients
Table 3: The US Tardive Dyskinesia Market by Number of Patients (2016-2025)
2.2 The US Tardive Dyskinesia - Number of Patients by Severity
Table 4: The US Tardive Dyskinesia - Number of Patients by Severity (2016-2025)
2.3 The US Tardive Dyskinesia Sales by Value
Table 5: The US Tardive Dyskinesia Sales by Value (2017-2025)
2.4 The US Tardive Dyskinesia Annual Price
Table 6: The US Tardive Dyskinesia Annual Price (2016-2025)
3. Japan Tardive Dyskinesia Market Analysis
3.1 Japan Tardive Dyskinesia Market by Number of Patients
Table 7: Japan Tardive Dyskinesia Market by Number of Patients (2016-2025)
3.2 Japan Tardive Dyskinesia - Number of Patients by Severity
Table 8: Japan Tardive Dyskinesia - Number of Patients by Severity (2016-2025)
3.3 Japan Tardive Dyskinesia Sales by Value
Table 9: Japan Tardive Dyskinesia Sales by Value (2017-2025)
3.4 Japan Tardive Dyskinesia Annual Price
Table 10: Japan Tardive Dyskinesia Annual Price (2017-2025)
4. The US Tardive Dyskinesia Drugs Market Analysis
4.1 The US Valbenazine Market by Penetration
Table 11: The US Valbenazine Market by Penetration (2017-2025)
4.2 The US SD-809 Market by Penetration
Table 12: The US SD-809 Market by Penetration (2019-2025)
4.3 The US Tetrabenazine Market for Tardive Dyskinesia by Penetration
Table 13: The US Tetrabenazine Market for Tardive Dyskinesia by Penetration (2017-2025)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Schizophrenia Patients
Table 14: Schizophrenia Patients in the US (2017-2025)
5.1.2 Increasing Bipolar Patients
Table 15: Bipolar Patients in the US (2017-2025)
5.1.3 Growing Antipsychotic Prescription
5.1.4 Increased Use of Long-Term Neuroleptic Drugs
5.1.5 Increasing Incidence of Neurological Disorders
5.2 Market Trends
5.2.1 Medications Causing Tardive Dyskinesia
Table 16: Medications Causing Tardive Dyskinesia
5.3 Challenges
5.3.1 Side Effects of Drugs
5.3.2 Under-Diagnosed
6. Competitive Landscape
6.1 Comparison between Valbenazine vs. SD-809
Table 17: Comparison between Valbenazine vs. SD-809
7. Company Profiles
7.1 Valeant Pharmaceuticals
7.1.1 Business Overview
Table 18: Valeant Pharmaceuticals Revenue by Segment (2016)
7.1.2 Financial Overview
Table 19: Valeant Pharmaceuticals Revenue and Net Income (2012-2016)
7.1.3 Business Strategies
7.2 Neurocrine Biosciences
7.2.1 Business Overview
Table 20: Neurocrine Biosciences Product Candidates in Clinical Development
7.2.2 Financial Overview
Table 21: Neurocrine Biosciences Revenue (2012-2016)
7.2.3 Business Strategies
7.3 Teva Pharmaceuticals Industries Ltd.
7.3.1 Business Overview
Table 22: Teva Pharmaceuticals Revenue by Segment (2016)
Table 23: Teva Pharmaceuticals Revenue by Region (2016)
7.3.2 Financial Overview
Table 24: Teva Pharmaceuticals Revenue and Net Income (2012-2016)
7.3.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report